India, April 3 -- By Nikhil Dedha

New Delhi [India], April 3 (ANI): The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to cause immediate disruption to Indian drugmakers, as the move largely targets branded medicines while exempting generics and biosimilars, said Siddharth Mittal, CEO and Managing Director of Biocon Limited.

In an exclusive interaction with ANI, Mittal said the tariff action is aimed at boosting domestic manufacturing in the United States but does not significantly impact Indian players in the near term.

"The recent tariff action by President Trump is clearly aimed at incentivising domestic manufacturing in the US. However, the current f...